Gossamer Bio Inc (GOSS NASDAQ) stock market data APIs
$10.4662
0.13(1.2%)
as of October 30, 2026
Try our APIs with
free plan!
Gossamer Bio Inc Financial Data Overview
Price chart is built with
Anychart
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.
Prev. Close
10.4662
Open
10.5936
High
10.8327
Low
10.1922
52 wk Range
8.29-309.6
Market Cap
63 488 K
Shares Outstanding
6 116 K
Revenue
53 286 K
Beta
2.206
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Gossamer Bio Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Gossamer Bio Inc data using free add-ons & libraries
Get Gossamer Bio Inc Fundamental Data
Gossamer Bio Inc Fundamental data includes:
- Net Revenue: 53 286 K
- EBITDA: -158 596 992
- Earnings Per Share: -52
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-11-04
- EPS/Forecast: -5.55
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Gossamer Bio Inc News
New
Adobe downgraded, VF Corp. upgraded: Wall Street's top analyst calls
The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: ...
Gossamer Bio submits NDA for seralutinib for pulmonary arterial hypertension
[PULMONARY HYPERTENSION medical term, medical conceptual image.] Md Saiful Islam Khan/iStock via Getty Images * Gossamer Bio (GOSS [https://seekingalpha.com/symbol/GOSS]) has submitted an NDA to th...
Assessment of the Pulmonary Arterial Hypertension (PAH) Market 2026-2036 Featuring United Therapeutics, Mochida Pharmaceutical, Johnson & Johnson, Merck, and Gossamer Bio
Company Logo Dublin, Sept. 08, 2026 (GLOBE NEWSWIRE) -- The "Pulmonary Arterial Hypertension - Market Insight, Epidemiology, and Market Forecast - 2036" has been added to ResearchAndMarkets.com's off...
Gossamer (GOSS) Announced Up to $250M of Financing, but Only $25M is Expected Upfront. Is the Runway Secure?
Gossamer Bio, Inc. (NASDAQ:GOSS) announced a structured private placement on August 21 that could generate up to approximately $250 million in gross proceeds. However, Gossamer Bio, Inc. (NASDAQ:GOSS)...
Get Gossamer Bio Inc fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.